Shares of MAIA Biotechnology, Inc. (MAIA) soared 12% on Wednesday morning after the company said that it entered into a ...

Roche discontinued the commercial and clinical use of Elevidys after two cases of fatal acute liver failure. The Swiss ...

Roche and Prothena are advancing Prasinezumab to Phase 3 for Parkinson’s despite mixed Phase 2 results. Click here to read an ...

Shares in both companies were down following news of the second death, casting fresh safety concerns over Elevidys.

The Swiss drugmaker said it was “encouraged” by the signs of effectiveness of the drug, developed by biotech Prothena, showed ...

Roche's Venclexta failure does not affect the oncology pipeline, as HER2 franchise continues to drive revenue growth. Click ...

Roche and Prothena are forging ahead to late-stage studies for their investigational Parkinson’s disease antibody ...

Roche and AbbVie have once again come up short in their attempt to gain an additional indication for their blockbuster blood ...

Basel: Roche has announced its decision to proceed with Phase III development of prasinezumab, an investigational ...